Compounded semaglutide is a GLP-1 receptor agonist - it acts on one hormone pathway involved in appetite and glucose regulation. Compounded tirzepatide acts on both GLP-1 and GIP receptors (dual action), which may offer additional metabolic support. Based on our projected member mix, approximately 62% of members choose tirzepatide and 36% choose semaglutide. Your provider will help you determine which option is most appropriate based on your medical history and goals.
⚠ Neither compounded semaglutide nor compounded tirzepatide offered through Lttl is FDA-approved. Both require a prescription following provider evaluation.
Comments
0 comments
Please sign in to leave a comment.